HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) has earned an average rating of “Hold” from the six research firms that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold rating. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $9.20.
A number of analysts recently commented on HLVX shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a research note on Monday, July 8th. Leerink Partners downgraded shares of HilleVax from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $28.00 to $2.00 in a report on Tuesday, July 9th. Guggenheim lowered shares of HilleVax from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. HC Wainwright restated a “neutral” rating and set a $2.00 target price on shares of HilleVax in a research report on Monday, August 12th. Finally, Stifel Nicolaus downgraded HilleVax from a “buy” rating to a “hold” rating and cut their price target for the company from $34.00 to $3.00 in a report on Tuesday, July 9th.
Get Our Latest Analysis on HLVX
Hedge Funds Weigh In On HilleVax
HilleVax Trading Down 1.1 %
Shares of HLVX opened at $1.87 on Thursday. HilleVax has a 12-month low of $1.55 and a 12-month high of $20.22. The stock has a market cap of $92.98 million, a P/E ratio of -0.57 and a beta of 0.80. The company has a 50-day moving average of $3.97 and a two-hundred day moving average of $11.03.
HilleVax (NASDAQ:HLVX – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). As a group, analysts forecast that HilleVax will post -2.47 EPS for the current fiscal year.
HilleVax Company Profile
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
See Also
- Five stocks we like better than HilleVax
- 3 Monster Growth Stocks to Buy Now
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- The How And Why of Investing in Oil Stocks
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- Basic Materials Stocks Investing
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.